An auxiliary instrument for the detection of intracranial hematomas was approved by the US FDA for sale

Recently, Infrascan has developed a handheld medical device called the Infrascanner Model 1000. The device mainly uses the principle of near-infrared spectroscopy analysis to assist in the examination of intracranial hematoma, and at the same time provides information on specific disease risks.

At present, the equipment has passed the approval of the US Food and Drug Administration (FDA) and can be officially sold. Although it does not replace the CT examination, it can be used to provide a basis for emergency doctors to assess non-invasively whether a patient needs an urgent CT examination. Therefore, the risk of disease can be reduced. With the establishment of the facility standards in the future, it will provide business opportunities for medical equipment manufacturers.

It is reported that the instrument can perform continuous scans on specific sites on both sides of the skull, and then examine the difference in optical density and light absorption between the hematoma and normal brain tissue, and then spread the information wirelessly. The doctor can use this data to assess whether there is a hematoma in the brain and whether a CT scan is needed immediately.

The FDA funded a re-presentation of the device after reviewing and comparing the test data of 383 patients. With the FDA allowing the instrument to be sold, it is believed that new business opportunities in the medical device industry will follow.